MEFV and familial Mediterranean fever: As confirmation of MEFV mutations is not required for canakinumab reimbursement in Belgium and the collection of mutation data, although probably available, was not subject to this study, some patients were potentially misdiagnosed with FMF prior to study inclusion and would respond less well than anticipated to anti-IL-1 treatment.